Atypical Hemolytic Syndrome Exclusive Info

The prognosis of aHUS is generally poor, with high mortality rates if left untreated. However, with prompt treatment, including plasma exchange and eculizumab, the outcome can be improved.

Background. Atypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is pl... PubMed Central (PMC) (.gov) Atypical Hemolytic Uremic Syndrome: Differential Diagnosis ... - PMC INTRODUCTION * Hemolytic uremic syndrome (HUS) is a rare and severe thrombotic microangiopathy (TMA) characterized by the triad of... PubMed Central (PMC) (.gov) Overcoming technical challenges when treating atypical hemolytic ... Introduction. Hemolytic uremic syndrome (HUS) is a hematological disease characterized mainly by the triad of microangiopathic hem... PubMed Central (PMC) (.gov) HUS and atypical HUS - PMC Among the 30% to 50% of patients with HUS who have no detectable complement defect, some have either impaired diacylglycerol kinas... PubMed Central (PMC) (.gov) Atypical Hemolytic Uremic Syndrome: Causes, Symptoms, and Treatment Oct 3, 2024 —

Induction (weekly x 4) → maintenance (every 2 weeks). For children, weight-based.

Advancements in genetic testing have made it easier to identify specific mutations, helping families understand their risks. While aHUS remains a complex and challenging diagnosis, modern medicine has significantly improved survival rates and quality of life for those affected.

Atypical hemolytic uremic syndrome (aHUS) is a rare and complex blood disorder characterized by the formation of blood clots in small blood vessels throughout the body. It is a type of thrombotic microangiopathy (TMA) that can cause multi-organ dysfunction, including kidney failure. aHUS is distinct from typical hemolytic uremic syndrome (HUS), which is often caused by Shiga toxin-producing E. coli (STEC).